151 related articles for article (PubMed ID: 29739298)
1. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.
Gardini AC; Faloppi L; Aprile G; Brunetti O; Caparello C; Corbelli J; Chessa L; Bruno D; Ercolani G; Leonetti A; Stefano G; Farella N; Foschi FG; Lanzi A; Dadduzio V; Marisi G; Masi G; Negri FV; Pagan F; Santini D; Scarpi E; Silletta M; Silvestris N; Tamburini E; Tassinari D; Vivaldi C; Gentilucci UV; Zagonel V; Calvetti L; Cascinu S; Frassineti GL; Scartozzi M
Tumori; 2018 Dec; 104(6):476-479. PubMed ID: 29739298
[TBL] [Abstract][Full Text] [Related]
2. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
Casadei Gardini A; Marisi G; Faloppi L; Scarpi E; Foschi FG; Iavarone M; Lauletta G; Corbelli J; Valgiusti M; Facchetti F; Della Corte C; Neri LM; Tamberi S; Cascinu S; Scartozzi M; Amadori D; Nanni O; Tenti E; Ulivi P; Frassineti GL
Oncotarget; 2016 May; 7(19):27988-99. PubMed ID: 27058899
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study.
Faloppi L; Puzzoni M; Casadei Gardini A; Silvestris N; Masi G; Marisi G; Vivaldi C; Gadaleta CD; Ziranu P; Bianconi M; Loretelli C; Demurtas L; Lai E; Giampieri R; Galizia E; Ulivi P; Battelli N; Falcone A; Cascinu S; Scartozzi M
Target Oncol; 2020 Feb; 15(1):115-126. PubMed ID: 32020517
[TBL] [Abstract][Full Text] [Related]
4. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
5. Association of
Casadei-Gardini A; Marisi G; Dadduzio V; Gramantieri L; Faloppi L; Ulivi P; Foschi FG; Tamburini E; Vivaldi C; Rizzato MD; Ielasi L; Canale M; Conti F; Rudnas B; Fornaro L; Silvestris N; Silletta M; Cardellino GG; Lonardi S; Fornari F; Orsi G; Rovesti G; Zagonel V; Cascinu S; Scartozzi M
Clin Cancer Res; 2020 Sep; 26(17):4485-4493. PubMed ID: 32371540
[TBL] [Abstract][Full Text] [Related]
6. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma.
Song S; Bai M; Li X; Gong S; Yang W; Lei C; Tian H; Si M; Hao X; Guo T
Expert Rev Mol Diagn; 2022 Mar; 22(3):361-378. PubMed ID: 35234564
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
El Shorbagy S; abuTaleb F; Labib HA; Ebian H; Harb OA; Mohammed MS; Rashied HA; Elbana KA; Haggag R
J Gastrointest Cancer; 2021 Mar; 52(1):269-279. PubMed ID: 32212089
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
9. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Lee JH; Chung YH; Kim JA; Shim JH; Lee D; Lee HC; Shin ES; Yoon JH; Kim BI; Bae SH; Koh KC; Park NH
Cancer; 2013 Jan; 119(1):136-42. PubMed ID: 22736425
[TBL] [Abstract][Full Text] [Related]
10. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
Llovet JM; Peña CE; Lathia CD; Shan M; Meinhardt G; Bruix J;
Clin Cancer Res; 2012 Apr; 18(8):2290-300. PubMed ID: 22374331
[TBL] [Abstract][Full Text] [Related]
11. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Godin C; Bodeau S; Saidak Z; Louandre C; François C; Barbare JC; Coriat R; Galmiche A; Sauzay C
Oncol Rep; 2019 Mar; 41(3):2041-2050. PubMed ID: 30569112
[TBL] [Abstract][Full Text] [Related]
12. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
13. Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma.
Giannitrapani L; Di Gaudio F; Cervello M; Scionti F; Ciliberto D; Staropoli N; Agapito G; Cannataro M; Tassone P; Tagliaferri P; Seidita A; Soresi M; Affronti M; Bertino G; Russello M; Ciriminna R; Lino C; Spinnato F; Verderame F; Augello G; Arbitrio M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396873
[TBL] [Abstract][Full Text] [Related]
14. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Cao G; Li X; Qin C; Li J
Med Sci Monit; 2015 Oct; 21():3144-51. PubMed ID: 26476711
[TBL] [Abstract][Full Text] [Related]
16. Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.
Marisi G; Azzali I; Passardi A; Rebuzzi F; Bartolini G; Urbini M; Canale M; Molinari C; Matteucci L; Sullo FG; Debonis SA; Gallio C; Gallo G; Frassineti GL; Ulivi P
Sci Rep; 2023 Aug; 13(1):12921. PubMed ID: 37558720
[TBL] [Abstract][Full Text] [Related]
17. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
Ulivi P; Scarpi E; Passardi A; Marisi G; Calistri D; Zoli W; Del Re M; Frassineti GL; Tassinari D; Tamberi S; Vertogen B; Amadori D
J Transl Med; 2015 Aug; 13():258. PubMed ID: 26259598
[TBL] [Abstract][Full Text] [Related]
18. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
Negri FV; Dal Bello B; Porta C; Campanini N; Rossi S; Tinelli C; Poggi G; Missale G; Fanello S; Salvagni S; Ardizzoni A; Maria SE
Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
[TBL] [Abstract][Full Text] [Related]
19. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
20. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]